Media stories about Cutera (NASDAQ:CUTR) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cutera earned a news impact score of 0.10 on Accern’s scale. Accern also gave headlines about the medical device company an impact score of 46.6370344532304 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of Cutera from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Cutera in a research note on Wednesday, November 8th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $37.33.
Cutera (NASDAQ CUTR) opened at $49.15 on Wednesday. Cutera has a 52 week low of $18.00 and a 52 week high of $52.90. The company has a market cap of $697.60, a PE ratio of 63.01, a price-to-earnings-growth ratio of 1.50 and a beta of 0.52.
In other Cutera news, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $42.55, for a total transaction of $42,550.00. Following the completion of the sale, the director now directly owns 8,055 shares in the company, valued at $342,740.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Miguel Pardos sold 10,000 shares of Cutera stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $46.70, for a total transaction of $467,000.00. Following the sale, the executive vice president now owns 39,698 shares of the company’s stock, valued at $1,853,896.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,468 shares of company stock valued at $1,459,096. Company insiders own 3.30% of the company’s stock.
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.